(Q43806060)

27 November 2017

Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study (English)

1 reference

27 November 2017

L Durelli

1

1 reference

27 November 2017

A Oggero

2

1 reference

27 November 2017

E Verdun

3

1 reference

27 November 2017

G L Isoardo

4

1 reference

27 November 2017

P Barbero

5

1 reference

27 November 2017

B Bergamasco

6

1 reference

27 November 2017

P C Brossa

7

1 reference

27 November 2017

E Ghigo

8

1 reference

27 November 2017

M Maccario

9

1 reference

27 November 2017

F Faggiano

10

1 reference

27 November 2017

Betaferon Safety Trial (BEST) Study Group

11

1 reference

27 November 2017

1 December 2001

1 reference

Journal of the Neurological Sciences

27 November 2017

1 reference

27 November 2017

193

1 reference

27 November 2017

1

1 reference

27 November 2017

17-22

1 reference

Thyroid function in multiple sclerosis

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Thyroid function in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Immune-mediated side-effects of cytokines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Clinical toxicity of the interferons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Association of MS with thyroid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Autoimmunity in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Antithyroid antibodies in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

The spectrum of thyroid disease in a community: the Whickham survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

The epidemiology of thyroid disease and implications for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Subclinical thyroid dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

American Thyroid Association guidelines for use of laboratory tests in thyroid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900637-2

10.1016/S0022-510X(01)00637-2

7 January 2021

Identifiers

DOI

1 reference

release_lbj54fikqjbljao4yy4wajvmgm

27 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lbj54fikqjbljao4yy4wajvmgm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference